title: Future of cancer vaccines.
abstract: Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain. This chapter discusses possible future perspectives for cancer vaccines as a treatment modality in oncology with special focus on biomarkers (response prediction and patient selection), requirements for clinical trial design, and combination therapies (standard of care and new molecular entities).Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain. This chapter discusses possible future perspectives for cancer vaccines as a treatment modality in oncology with special focus on biomarkers (response prediction and patient selection), requirements for clinical trial design, and combination therapies (standard of care and new molecular entities).
authors.affiliation: Laboratory of Clinical and Experimental Tumor Immunology, Department of Surgery, Grosshadern Medical Center, Ludwig-Maximilians-University Munich, Munich, Germany.
authors.forename: Hauke
authors.initials: H
authors.lastname: Winter
authors.forename: Bernard A
authors.initials: BA
authors.lastname: Fox
authors.forename: Dominik
authors.initials: D
authors.lastname: Rüttinger
mesh_terms: D014408:Biomarkers, Tumor; D019496:Cancer Vaccines / Q000276:immunology; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D014020:Tissue Extracts / Q000276:immunology
chemical_list: D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T